146556-41-4
Chemical Structure
PF1070A
- CAS No.: 146556-41-4
- Formula:C31H44N4O6
- Molecular Weight:568.70
IUPAC Name: 6-benzyl-9-(sec-butyl)-3-(6-(oxiran-2-yl)-6-oxohexyl)octahydro-2H-pyrido[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10(3H,12H)-tetraone
InChIKey: IEIMOAHNLVBBHL-JHNLHKAESA-N
SMILES: O=C1N[C@H](CC2=CC=CC=C2)C(N[C@H]([C@H](CC)C)C(N3CCCC[C@H]3C(N[C@H]1CCCCCC(C4OC4)=O)=O)=O)=O
Biological Activity: PF1070A is a Pf HDAC1 inhibitor with an IC50 of 0.0011 μM. By inhibiting histone deacetylase (HDAC) activity, PF1070A induces histone H4 hyperacetylation and chromatin remodeling, arrests cell cycle progression prior to nuclear division, and exhibits antimalarial activity against multidrug-resistant Plasmodium falciparum strains with high selectivity. PF1070A is suitable for use in malaria research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PF1070A | PF1070A is a Pf HDAC1 inhibitor with an IC50 of 0.0011 μM. By inhibiting histone deacetylase (HDAC) activity, PF1070A induces histone H4 hyperacetylation and chromatin remodeling, arrests cell cycle progression prior to nuclear division, and exhibits antimalarial activity against multidrug-resistant Plasmodium falciparum strains with high selectivity. PF1070A is suitable for use in malaria research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Collins JE, et al. Cyclic Tetrapeptide HDAC Inhibitors with Improved Plasmodium falciparum Selectivity and Killing Profile. ACS Infect Dis. 2021 Oct 8;7(10):2889-2903.
- [2]. Ochi, S, et al. Identification and activity of a phytotoxin produced by Calonectria ilicicola, the causal agent of soybean red crown rot. Canadian Journal of Plant Pathology, 33(3), 347–354.
- [3]. Asahi I, et al. PF1070A, a novel and potent inducer of the synthesis of metallothionein. Biochemistry. 1999 Aug 10;38(32):10415-23.
- [4]. Wang X, et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15018-23.
